论文部分内容阅读
目的:探讨核苷类抗病毒药物在乙肝肝硬化患者治疗中的临床价值。方法:选取重庆市长寿区人民医院2012年1月-2014年2月170例乙肝肝硬化患者,数字抽取分为观察组与对照组,对照组采用常规治疗,观察组在此基础上予以核苷类抗病毒药物治疗,分析对比两组患者临床治疗效果。结果:两组患者的谷草转氨酶(AST)、谷丙转氨酶(ALT)、总胆红素(TBi L)、白蛋白(Alb)、胆碱酯酶(Ch E)水平比较,差异有统计学意义((P<0.05);乙型肝炎病毒(HBV)DNA和乙型肝炎e抗原转阴率、(HBV)DNA下降幅度比较,差异有统计学意义(P<0.05)。结论:核苷类抗病毒药物对于乙肝肝硬化临床效果明显,可显著改善肝功能,减少肝纤维化,降低肝癌发生率。
Objective: To investigate the clinical value of nucleoside antiviral drugs in the treatment of hepatitis B cirrhosis patients. Methods: A total of 170 patients with hepatitis B cirrhosis from January 2012 to February 2014 were selected from Changshou District People’s Hospital of Chongqing Municipality. The patients in control group were divided into observation group and control group. Conventional treatment was given to the control group. On the basis of this, Antiviral drug treatment, analysis and comparison of two groups of patients with clinical treatment. Results: There was significant difference in AST, ALT, TBi L, Alb and Ch E between the two groups (P <0.05), and there was a significant difference between the reduction rate of hepatitis B virus (HBV) DNA and hepatitis B e antigen negative rate (HBV DNA) (P <0.05) .Conclusion: Viral drugs for hepatitis B liver cirrhosis clinical effect is obvious, can significantly improve liver function, reduce liver fibrosis and reduce the incidence of liver cancer.